

## Supplementary data

**Table S1.** PCR primers used for the detection of  $\beta$ -lactamase genes

Gene/locus	Primer name	Primer sequence 5'→3'	Reference
<i>ISAb<sub>a</sub>1</i>	ISAb <sub>a</sub> 1F	CACGAATGCAGAAGTTG	Segal H <i>et al. FEMS Microbiol Lett</i> 2005; <b>243</b> : 425-9.
	ISAb <sub>a</sub> 1R	CGACGAATACTATGACAC	
<i>bla</i> <sub>OXA-51-like</sub>	OXA51-likeF	ATGAACATTAAAGCACTC	Turton JF <i>et al. FEMS Microbiol Lett</i> 2006; <b>258</b> : 72-7.
	OXA51-likeR	CTATAAAATACCTAATTGTTT	
<i>bla</i> <sub>OXA-23-like</sub>	OXA23-likeF	GATCGGATTGGAGAACCAGA	Woodford N <i>et al. J Antimicrob Agents</i> 2006; <b>27</b> : 351-3.
	OXA23-likeR	ATTTCTGACCGCATTTCAT	
<i>bla</i> <sub>OXA-40-like</sub>	OXA24-likeF	GGTTAGTTGGCCCCCTTAAA	Woodford N <i>et al. J Antimicrob Agents</i> 2006; <b>27</b> : 351-3.
	OXA24-likeR	AGTTGAGCGAAAAGGGGATT	
<i>bla</i> <sub>OXA-58-like</sub>	OXA58-likeF	AAGTATTGGGGCTTGTGCTG	Woodford N <i>et al. J Antimicrob Agents</i> 2006; <b>27</b> : 351-3.
	OXA58-likeR	CCCCTCTGCGCTCTACATAC	
<i>bla</i> <sub>OXA-143-like</sub>	pre-OXA-143A	AGTTAACTTTCAATAATTG	Higgins PG <i>et al. J Antimicrob Agents</i> 2010; <b>35</b> : 305.
	pre-OXA-143B	TTGGAAAATTATATAATCCC	
<i>bla</i> <sub>OXA-235-like</sub>	OXA-235F	TTGTTGCCTTTACTTAGTTGC	Higgins PG <i>et al. Int Antimicrob Agents Chemother</i> 2013; <b>57</b> : 2121-6.
	OXA-235R	CAAAATTTTAAGACGGATCG	
<i>bla</i> <sub>OXA-10</sub>	OXA-10F	ATCCCCAACGCAATTATCGGC	this study
	OXA-10R	ATATTCAGGTGCCGCCTCCG	
<i>bla</i> <sub>NDM</sub>	NDM-R	AGCGCAGCTTGTGCGCCAT	this study
	NDM-F	TTGCCCAATATTATGCACCCG	
<i>bla</i> <sub>VEB-1</sub>	VEB-1F	ATGAAAATCGTAAAAAGGATATT	Hujer KM <i>et al. Antimicrob Agents Chemother</i> 2006; <b>50</b> : 4114-23.
	VEB-1R	TTATTTATTCAAATAGTAATTCC	
<i>bla</i> <sub>PER-1</sub>	PER-1F	ATGAATGTCATTATAAAAG	Hujer KM <i>et al. Antimicrob Agents Chemother</i> 2006; <b>50</b> : 4114-23.
	PER-1R	TTGGGCTTAGGGCAG	
<i>bla</i> <sub>IMP</sub>	IMP-F	GTTTATGTTCATACWTCG	Hujer KM <i>et al. Antimicrob Agents Chemother</i> 2006; <b>50</b> : 4114-23.
	IMP-R	GGTTTAAAYAAAACAACCAC	
<i>bla</i> <sub>VIM</sub>	VIM-F	TTTGGTCGCATATCGCAACG	Hujer KM <i>et al. Antimicrob Agents Chemother</i> 2006; <b>50</b> : 4114-23.
	VIM-R	CCATTCAGCCAGATCGGCAT	

**Table S2.** Antibiotic susceptibilities of *A. baumannii* NIPH 56 and *E. coli* Top 10 and their transformants based on Etest and disc diffusion<sup>a</sup>

β-Lactam	MIC (mg/L)				Inhibition zone diameters (mm)			
	<i>A. baumannii</i>		<i>E. coli</i>		<i>A. baumannii</i>		<i>E. coli</i>	
	NIPH 56	NIPH 56 (pAT801) <sup>b</sup>	Top 10	Top 10 (pAT801) <sup>c</sup>	NIPH 56	NIPH 56 (pAT801) <sup>b</sup>	Top 10	Top 10 (pAT801) <sup>c</sup>
Sulbactam	0.5	32	16	≥256	NT	NT	NT	NT
Ampicillin	32	>256	2	>256	8	6	24	6
Ampicillin/sulbactam (2:1)	1	64	2	128	NT	NT	NT	NT
Piperacillin	8	>256	1	>256	24	6	36	8
Piperacillin/tazobactam (2 mg/L)	≤0.125	≤0.125	2	2	26 <sup>e</sup>	24 <sup>e</sup>	35 <sup>e</sup>	18 <sup>e</sup>
Ticarcillin	NT	NT	NT	NT	26	6	31	6
Ticarcillin/clavulanic acid (2 mg/L)	8	>256	1	>256	NT	NT	NT	NT
Ceftazidime	4	4	0.125	0.25	21	21	34	34
Cefotaxime	8	8	0.125	0.125	20	20	40	39
Cefepime	8	8	0.125	0.5	20	18	42	38
Imipenem	1	1	1	1	31	31	35	33
Meropenem	0.25	0.5	0.125	0.125	29	28	42	40
Aztreonam	NT	NT	NT	NT	19	19	38	37

<sup>a</sup>Determined by Etest (bioMérieux) using Mueller-Hinton II agar (BBL, BD, USA) following the manufacturer guidelines and the CLSI interpretative criteria.<sup>17</sup> Disc diffusion was performed according to CLSI guidelines<sup>17</sup> with the following antibiotic discs (Oxoid) (content of antibiotic in µg/disc): ampicillin (10), piperacillin (100), piperacillin/tazobactam (100/10), ticarcillin (75), ceftazidime (30), cefotaxime (30), cefepime (30), imipenem (10), meropenem (10) and aztreonam (30).

<sup>b</sup>*A. baumannii* NIPH 56 transformed by plasmid pAT801 harbouring the *bla*<sub>TEM-1</sub> gene.

<sup>c</sup>*E. coli* Top 10 transformed by plasmid pAT801 harbouring the *bla*<sub>TEM-1</sub> gene.

NT, not tested.